Psychodynamic psychopharmacology: caring for the treatment-resistant patient
"The troubling increase in treatment resistance in psychiatry has many culprits: the rise of biomedical psychiatry and corresponding sidelining of psychodynamic and psychosocial factors; the increased emphasis on treating the symptoms rather than the person; and a greater focus on the electroni...
Gespeichert in:
1. Verfasser: | |
---|---|
Format: | Buch |
Sprache: | English |
Veröffentlicht: |
Washington, DC
American Psychiatric Association Publishing
[2022]
|
Ausgabe: | First edition |
Schlagworte: | |
Zusammenfassung: | "The troubling increase in treatment resistance in psychiatry has many culprits: the rise of biomedical psychiatry and corresponding sidelining of psychodynamic and psychosocial factors; the increased emphasis on treating the symptoms rather than the person; and a greater focus on the electronic medical record rather than the patient, all of which point to a breakdown in the person-centered prescriber-patient relationship. Psychodynamic Psychopharmacology illuminates a new path forward. It examines the psychological and interpersonal mechanisms of pharmacological treatment resistance, integrating research on evidence-based prescribing processes with psychodynamic insights and skills to enhance treatment outcomes for patients who are difficult to treat. The first part of the book explores the evidence base that guides how, rather than simply what, to prescribe. It describes precisely what psychodynamic psychopharmacology is and why its emphasis on combining the often-neglected psychosocial aspects of medication with biomedical considerations provides a more optimized approach to addressing treatment resistance. Part II delves into the psychodynamics that contribute to pharmacological treatment resistance, both when patients' ambivalence about their illness, the medication itself, or their prescriber manifests in nonadherence and when medications support a negative identity or are used as replacements for healthy capacities. Readers will gain basic skills for addressing the psychological and interpersonal dynamics that underpin both scenarios and will be better positioned to ameliorate interferences with the healthy use of medications. The final section of the book offers detailed technical recommendations for addressing pharmacological treatment resistance. It tackles issues that include countertransference-driven irrational prescribing; primitive dynamics, such as splitting and projective identification; and the overlap between psychopharmacological treatment resistance and the dynamics of treatment nonadherence and nonresponse in integrated and collaborative medical care settings. By putting the individual patient back at the center of the therapeutic equation, psychodynamic psychopharmacology, as outlined in this book, offers a model that moves beyond compliance and emphasizes instead the alliance between patient and prescriber. In doing so, it empowers patients to become more active contributors in their own recovery"-- |
Beschreibung: | xiii, 281 Seiten Illustrationen 23 cm |
ISBN: | 9781615371525 1615371524 |
Internformat
MARC
LEADER | 00000nam a2200000 c 4500 | ||
---|---|---|---|
001 | BV048453466 | ||
003 | DE-604 | ||
005 | 20220929 | ||
007 | t | ||
008 | 220905s2022 a||| b||| 00||| eng d | ||
020 | |a 9781615371525 |9 978-1-61537-152-5 | ||
020 | |a 1615371524 |9 1615371524 | ||
035 | |a (OCoLC)1258782855 | ||
035 | |a (DE-599)BVBBV048453466 | ||
040 | |a DE-604 |b ger |e rda | ||
041 | 0 | |a eng | |
049 | |a DE-20 | ||
084 | |a CZ 2000 |0 (DE-625)19239: |2 rvk | ||
100 | 1 | |a Mintz, David L. |e Verfasser |0 (DE-588)1023179016 |4 aut | |
245 | 1 | 0 | |a Psychodynamic psychopharmacology |b caring for the treatment-resistant patient |c by David Mintz |
250 | |a First edition | ||
264 | 1 | |a Washington, DC |b American Psychiatric Association Publishing |c [2022] | |
300 | |a xiii, 281 Seiten |b Illustrationen |c 23 cm | ||
336 | |b txt |2 rdacontent | ||
337 | |b n |2 rdamedia | ||
338 | |b nc |2 rdacarrier | ||
505 | 8 | |a What Is Psychodynamic Psychopharmacology? -- Why Psychodynamic Psychopharmacology? -- What Is Psychodynamic About Psychodynamic Psychopharmacology? -- Psychodynamics of Pharmacological Treatment Resistance -- Treatment Resistance to Medications -- Treatment Resistance From Medications -- The Prescriber's Contribution to Treatment Resistance -- Avoid a Mind-Body Split -- Know Who the Patient Is -- Attend to Patients' Ambivalence -- Cultivate the Pharmacotherapeutic Alliance -- Attend to Countertherapeutic Uses of Medications -- Identify, Contain, and Use Countertransference -- Who Is Psychodynamic Psychopharmacology For? Patient Characteristics -- Before Initiating Treatment -- The Engagement Phase -- The Maintenance Phase -- Split and Combined Treatments -- Psychodynamic Psychopharmacology and Integrated Care | |
520 | 3 | |a "The troubling increase in treatment resistance in psychiatry has many culprits: the rise of biomedical psychiatry and corresponding sidelining of psychodynamic and psychosocial factors; the increased emphasis on treating the symptoms rather than the person; and a greater focus on the electronic medical record rather than the patient, all of which point to a breakdown in the person-centered prescriber-patient relationship. Psychodynamic Psychopharmacology illuminates a new path forward. It examines the psychological and interpersonal mechanisms of pharmacological treatment resistance, integrating research on evidence-based prescribing processes with psychodynamic insights and skills to enhance treatment outcomes for patients who are difficult to treat. The first part of the book explores the evidence base that guides how, rather than simply what, to prescribe. | |
520 | 3 | |a It describes precisely what psychodynamic psychopharmacology is and why its emphasis on combining the often-neglected psychosocial aspects of medication with biomedical considerations provides a more optimized approach to addressing treatment resistance. Part II delves into the psychodynamics that contribute to pharmacological treatment resistance, both when patients' ambivalence about their illness, the medication itself, or their prescriber manifests in nonadherence and when medications support a negative identity or are used as replacements for healthy capacities. Readers will gain basic skills for addressing the psychological and interpersonal dynamics that underpin both scenarios and will be better positioned to ameliorate interferences with the healthy use of medications. The final section of the book offers detailed technical recommendations for addressing pharmacological treatment resistance. | |
520 | 3 | |a It tackles issues that include countertransference-driven irrational prescribing; primitive dynamics, such as splitting and projective identification; and the overlap between psychopharmacological treatment resistance and the dynamics of treatment nonadherence and nonresponse in integrated and collaborative medical care settings. By putting the individual patient back at the center of the therapeutic equation, psychodynamic psychopharmacology, as outlined in this book, offers a model that moves beyond compliance and emphasizes instead the alliance between patient and prescriber. In doing so, it empowers patients to become more active contributors in their own recovery"-- | |
653 | 0 | |a Psychopharmacology | |
653 | 0 | |a Psychodynamic psychotherapy | |
653 | 0 | |a Physician and patient | |
653 | 0 | |a Mental Disorders / drug therapy | |
653 | 0 | |a Psychotropic Drugs / therapeutic use | |
653 | 0 | |a Treatment Refusal / psychology | |
653 | 0 | |a Physician-Patient Relations | |
653 | 0 | |a Psychopharmacology | |
653 | 0 | |a Psychopharmacologie | |
653 | 0 | |a Psychothérapie dynamique | |
653 | 0 | |a Relations médecin-patient | |
653 | 0 | |a Physician and patient | |
653 | 0 | |a Psychodynamic psychotherapy | |
653 | 0 | |a Psychopharmacology | |
776 | 0 | 8 | |i Online version |a Mintz, David L. |t Psychodynamic psychopharmacology |b First edition |d Washington, DC : American Psychiatric Association Publishing, [2022] |z 9781615374007 |
999 | |a oai:aleph.bib-bvb.de:BVB01-033831593 |
Datensatz im Suchindex
_version_ | 1804184387270475776 |
---|---|
adam_txt | |
any_adam_object | |
any_adam_object_boolean | |
author | Mintz, David L. |
author_GND | (DE-588)1023179016 |
author_facet | Mintz, David L. |
author_role | aut |
author_sort | Mintz, David L. |
author_variant | d l m dl dlm |
building | Verbundindex |
bvnumber | BV048453466 |
classification_rvk | CZ 2000 |
contents | What Is Psychodynamic Psychopharmacology? -- Why Psychodynamic Psychopharmacology? -- What Is Psychodynamic About Psychodynamic Psychopharmacology? -- Psychodynamics of Pharmacological Treatment Resistance -- Treatment Resistance to Medications -- Treatment Resistance From Medications -- The Prescriber's Contribution to Treatment Resistance -- Avoid a Mind-Body Split -- Know Who the Patient Is -- Attend to Patients' Ambivalence -- Cultivate the Pharmacotherapeutic Alliance -- Attend to Countertherapeutic Uses of Medications -- Identify, Contain, and Use Countertransference -- Who Is Psychodynamic Psychopharmacology For? Patient Characteristics -- Before Initiating Treatment -- The Engagement Phase -- The Maintenance Phase -- Split and Combined Treatments -- Psychodynamic Psychopharmacology and Integrated Care |
ctrlnum | (OCoLC)1258782855 (DE-599)BVBBV048453466 |
discipline | Psychologie |
discipline_str_mv | Psychologie |
edition | First edition |
format | Book |
fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05055nam a2200517 c 4500</leader><controlfield tag="001">BV048453466</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20220929 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">220905s2022 a||| b||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781615371525</subfield><subfield code="9">978-1-61537-152-5</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1615371524</subfield><subfield code="9">1615371524</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1258782855</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV048453466</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-20</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">CZ 2000</subfield><subfield code="0">(DE-625)19239:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Mintz, David L.</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)1023179016</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Psychodynamic psychopharmacology</subfield><subfield code="b">caring for the treatment-resistant patient</subfield><subfield code="c">by David Mintz</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">First edition</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Washington, DC</subfield><subfield code="b">American Psychiatric Association Publishing</subfield><subfield code="c">[2022]</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">xiii, 281 Seiten</subfield><subfield code="b">Illustrationen</subfield><subfield code="c">23 cm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">What Is Psychodynamic Psychopharmacology? -- Why Psychodynamic Psychopharmacology? -- What Is Psychodynamic About Psychodynamic Psychopharmacology? -- Psychodynamics of Pharmacological Treatment Resistance -- Treatment Resistance to Medications -- Treatment Resistance From Medications -- The Prescriber's Contribution to Treatment Resistance -- Avoid a Mind-Body Split -- Know Who the Patient Is -- Attend to Patients' Ambivalence -- Cultivate the Pharmacotherapeutic Alliance -- Attend to Countertherapeutic Uses of Medications -- Identify, Contain, and Use Countertransference -- Who Is Psychodynamic Psychopharmacology For? Patient Characteristics -- Before Initiating Treatment -- The Engagement Phase -- The Maintenance Phase -- Split and Combined Treatments -- Psychodynamic Psychopharmacology and Integrated Care</subfield></datafield><datafield tag="520" ind1="3" ind2=" "><subfield code="a">"The troubling increase in treatment resistance in psychiatry has many culprits: the rise of biomedical psychiatry and corresponding sidelining of psychodynamic and psychosocial factors; the increased emphasis on treating the symptoms rather than the person; and a greater focus on the electronic medical record rather than the patient, all of which point to a breakdown in the person-centered prescriber-patient relationship. Psychodynamic Psychopharmacology illuminates a new path forward. It examines the psychological and interpersonal mechanisms of pharmacological treatment resistance, integrating research on evidence-based prescribing processes with psychodynamic insights and skills to enhance treatment outcomes for patients who are difficult to treat. The first part of the book explores the evidence base that guides how, rather than simply what, to prescribe. </subfield></datafield><datafield tag="520" ind1="3" ind2=" "><subfield code="a">It describes precisely what psychodynamic psychopharmacology is and why its emphasis on combining the often-neglected psychosocial aspects of medication with biomedical considerations provides a more optimized approach to addressing treatment resistance. Part II delves into the psychodynamics that contribute to pharmacological treatment resistance, both when patients' ambivalence about their illness, the medication itself, or their prescriber manifests in nonadherence and when medications support a negative identity or are used as replacements for healthy capacities. Readers will gain basic skills for addressing the psychological and interpersonal dynamics that underpin both scenarios and will be better positioned to ameliorate interferences with the healthy use of medications. The final section of the book offers detailed technical recommendations for addressing pharmacological treatment resistance. </subfield></datafield><datafield tag="520" ind1="3" ind2=" "><subfield code="a">It tackles issues that include countertransference-driven irrational prescribing; primitive dynamics, such as splitting and projective identification; and the overlap between psychopharmacological treatment resistance and the dynamics of treatment nonadherence and nonresponse in integrated and collaborative medical care settings. By putting the individual patient back at the center of the therapeutic equation, psychodynamic psychopharmacology, as outlined in this book, offers a model that moves beyond compliance and emphasizes instead the alliance between patient and prescriber. In doing so, it empowers patients to become more active contributors in their own recovery"--</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Psychopharmacology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Psychodynamic psychotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Physician and patient</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Mental Disorders / drug therapy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Psychotropic Drugs / therapeutic use</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Treatment Refusal / psychology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Physician-Patient Relations</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Psychopharmacology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Psychopharmacologie</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Psychothérapie dynamique</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Relations médecin-patient</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Physician and patient</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Psychodynamic psychotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Psychopharmacology</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Online version</subfield><subfield code="a">Mintz, David L.</subfield><subfield code="t">Psychodynamic psychopharmacology</subfield><subfield code="b">First edition</subfield><subfield code="d">Washington, DC : American Psychiatric Association Publishing, [2022]</subfield><subfield code="z">9781615374007</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-033831593</subfield></datafield></record></collection> |
id | DE-604.BV048453466 |
illustrated | Illustrated |
index_date | 2024-07-03T20:31:36Z |
indexdate | 2024-07-10T09:38:32Z |
institution | BVB |
isbn | 9781615371525 1615371524 |
language | English |
oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-033831593 |
oclc_num | 1258782855 |
open_access_boolean | |
owner | DE-20 |
owner_facet | DE-20 |
physical | xiii, 281 Seiten Illustrationen 23 cm |
publishDate | 2022 |
publishDateSearch | 2022 |
publishDateSort | 2022 |
publisher | American Psychiatric Association Publishing |
record_format | marc |
spelling | Mintz, David L. Verfasser (DE-588)1023179016 aut Psychodynamic psychopharmacology caring for the treatment-resistant patient by David Mintz First edition Washington, DC American Psychiatric Association Publishing [2022] xiii, 281 Seiten Illustrationen 23 cm txt rdacontent n rdamedia nc rdacarrier What Is Psychodynamic Psychopharmacology? -- Why Psychodynamic Psychopharmacology? -- What Is Psychodynamic About Psychodynamic Psychopharmacology? -- Psychodynamics of Pharmacological Treatment Resistance -- Treatment Resistance to Medications -- Treatment Resistance From Medications -- The Prescriber's Contribution to Treatment Resistance -- Avoid a Mind-Body Split -- Know Who the Patient Is -- Attend to Patients' Ambivalence -- Cultivate the Pharmacotherapeutic Alliance -- Attend to Countertherapeutic Uses of Medications -- Identify, Contain, and Use Countertransference -- Who Is Psychodynamic Psychopharmacology For? Patient Characteristics -- Before Initiating Treatment -- The Engagement Phase -- The Maintenance Phase -- Split and Combined Treatments -- Psychodynamic Psychopharmacology and Integrated Care "The troubling increase in treatment resistance in psychiatry has many culprits: the rise of biomedical psychiatry and corresponding sidelining of psychodynamic and psychosocial factors; the increased emphasis on treating the symptoms rather than the person; and a greater focus on the electronic medical record rather than the patient, all of which point to a breakdown in the person-centered prescriber-patient relationship. Psychodynamic Psychopharmacology illuminates a new path forward. It examines the psychological and interpersonal mechanisms of pharmacological treatment resistance, integrating research on evidence-based prescribing processes with psychodynamic insights and skills to enhance treatment outcomes for patients who are difficult to treat. The first part of the book explores the evidence base that guides how, rather than simply what, to prescribe. It describes precisely what psychodynamic psychopharmacology is and why its emphasis on combining the often-neglected psychosocial aspects of medication with biomedical considerations provides a more optimized approach to addressing treatment resistance. Part II delves into the psychodynamics that contribute to pharmacological treatment resistance, both when patients' ambivalence about their illness, the medication itself, or their prescriber manifests in nonadherence and when medications support a negative identity or are used as replacements for healthy capacities. Readers will gain basic skills for addressing the psychological and interpersonal dynamics that underpin both scenarios and will be better positioned to ameliorate interferences with the healthy use of medications. The final section of the book offers detailed technical recommendations for addressing pharmacological treatment resistance. It tackles issues that include countertransference-driven irrational prescribing; primitive dynamics, such as splitting and projective identification; and the overlap between psychopharmacological treatment resistance and the dynamics of treatment nonadherence and nonresponse in integrated and collaborative medical care settings. By putting the individual patient back at the center of the therapeutic equation, psychodynamic psychopharmacology, as outlined in this book, offers a model that moves beyond compliance and emphasizes instead the alliance between patient and prescriber. In doing so, it empowers patients to become more active contributors in their own recovery"-- Psychopharmacology Psychodynamic psychotherapy Physician and patient Mental Disorders / drug therapy Psychotropic Drugs / therapeutic use Treatment Refusal / psychology Physician-Patient Relations Psychopharmacologie Psychothérapie dynamique Relations médecin-patient Online version Mintz, David L. Psychodynamic psychopharmacology First edition Washington, DC : American Psychiatric Association Publishing, [2022] 9781615374007 |
spellingShingle | Mintz, David L. Psychodynamic psychopharmacology caring for the treatment-resistant patient What Is Psychodynamic Psychopharmacology? -- Why Psychodynamic Psychopharmacology? -- What Is Psychodynamic About Psychodynamic Psychopharmacology? -- Psychodynamics of Pharmacological Treatment Resistance -- Treatment Resistance to Medications -- Treatment Resistance From Medications -- The Prescriber's Contribution to Treatment Resistance -- Avoid a Mind-Body Split -- Know Who the Patient Is -- Attend to Patients' Ambivalence -- Cultivate the Pharmacotherapeutic Alliance -- Attend to Countertherapeutic Uses of Medications -- Identify, Contain, and Use Countertransference -- Who Is Psychodynamic Psychopharmacology For? Patient Characteristics -- Before Initiating Treatment -- The Engagement Phase -- The Maintenance Phase -- Split and Combined Treatments -- Psychodynamic Psychopharmacology and Integrated Care |
title | Psychodynamic psychopharmacology caring for the treatment-resistant patient |
title_auth | Psychodynamic psychopharmacology caring for the treatment-resistant patient |
title_exact_search | Psychodynamic psychopharmacology caring for the treatment-resistant patient |
title_exact_search_txtP | Psychodynamic psychopharmacology caring for the treatment-resistant patient |
title_full | Psychodynamic psychopharmacology caring for the treatment-resistant patient by David Mintz |
title_fullStr | Psychodynamic psychopharmacology caring for the treatment-resistant patient by David Mintz |
title_full_unstemmed | Psychodynamic psychopharmacology caring for the treatment-resistant patient by David Mintz |
title_short | Psychodynamic psychopharmacology |
title_sort | psychodynamic psychopharmacology caring for the treatment resistant patient |
title_sub | caring for the treatment-resistant patient |
work_keys_str_mv | AT mintzdavidl psychodynamicpsychopharmacologycaringforthetreatmentresistantpatient |